FORM PTO-1390 (Modified) (REV 11-2000) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER	U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR)
217151US0PCT	10/019436

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/JP00/04096	22 JUNE 2000	01 JULY 1999

TITLE OF INVENTION

QUINOLINECARBOXYLIC ACID DERIVATIVE OR SALTS THEREOF

APPLICANT(S) FOR DO/EO/US

Akira YAZAKI, et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include itens (5), (6), (9) and (24) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
   a. ☐ is attached hereto (required only if not communicated by the International Bureau).
   b. ☒ has been communicated by the International Bureau.
   c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
   a. ☒ is attached hereto.
   b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
   a. ☐ are attached hereto (required only if not communicated by the International Bureau).
   b. ☐ have been communicated by the International Bureau.
   c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
   d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☒ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 20 below concern document(s) or information included:

13. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☐ Certificate of Mailing by Express Mail
23. ☒ Other items or information:

Notice of Priority / PCT/IB/304 / PCT/IB/308
PTO-1449

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER
10/019436	PCT/JP00/04096	217151US0PCT

24. The following fees are submitted:.

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

		CALCULATIONS PTO USE ONLY
☐	Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO	**$1040.00**
☒	International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO	**$890.00**
☐	International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO	**$740.00**
☐	International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)	**$710.00**
☐	International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)	**$100.00**

ENTER APPROPRIATE BASIC FEE AMOUNT =	**$890.00**	
Surcharge of **$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).	**$0.00**	

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	7 - 20 =	0	x $18.00	**$0.00**	
Independent claims	5 - 3 =	2	x $84.00	**$168.00**	
Multiple Dependent Claims **(check if applicable)**.			☐	**$0.00**	
TOTAL OF ABOVE CALCULATIONS =				**$1,058.00**	
☐ Applicant claims small entity status. See 37 CFR 1.27). The fees indicated above are reduced by 1/2.				**$0.00**	
SUBTOTAL =				**$1,058.00**	
Processing fee of **$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)). +				**$0.00**	
TOTAL NATIONAL FEE =				**$1,058.00**	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) **(check if applicable).** ☐				**$0.00**	
TOTAL FEES ENCLOSED =				**$1,058.00**	
				Amount to be: refunded	$
				charged	$

a. ☒ A check in the amount of **$1,058.00** to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **15-0030** A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

22850

(703) 413-3000

Surinder Sachar
Registration No. 34,423

Surinder Sachar
SIGNATURE

Norman F. Oblon
NAME

24,618
REGISTRATION NUMBER

Dec. 31 2001
DATE

DESCRIPTION

QUINOLINECARBOXYLIC ACID DERIVATIVE OR SALTS THEREOF

Technical Field

This invention relates to a quinolinecarboxylic acid derivative and salts thereof, which have excellent antimicrobial effects and oral absorption, and also to antimicrobial agents comprising the same.

Background Art

Compounds having the basic skeleton of quinoline-carboxylic acid are known to include many compounds useful as synthetic antimicrobials for their excellent antimicrobial activities and broad antimicrobial spectra. Among such compounds, norfloxacin (JP 53-141286 A), enoxacin (JP 55-31042 A), ofloxacin (JP 57-46986 A), ciprofloxacin (JP 58-74667 A), tosufloxacin (JP 60-228479) and the like are widely used in clinical practice as therapeutic agents for infectious diseases.

These compounds, however, are not sufficient yet in antimicrobial activities, intestinal absorption and metabolic stability, and still involve many problems to be solved, such as reductions of phototoxicity and cytotoxicity both of which are specific to quinolinecarboxylic acid and its derivatives. Recently, the emergence of resistant bacteria to these

medicaments has also raised a problem.

Disclosure of the Invention

An object of the present invention is, therefore, to provide an antimicrobial agent, which is clinically applicable, has excellent antimicrobial potency, intestinal absorption and metabolic stability, and has low side effects.

Under the foregoing circumstances, the present inventors conducted extensive research to provide clinically excellent medicinal agents. As a result, it was found that pyridonecarboxylic acid derivatives - which are each represented by the following formula (I):



(I)

wherein R^1 represents a hydrogen atom or a carboxyl-protecting group, R^2 represents a hydroxyl group, a lower alkoxy group or a substituted or unsubstituted amino group, R^3 represents a hydrogen atom or a halogen atom, R^4 represents a hydrogen atom or a halogen atom, R^5 represents a halogen atom or a substituted or unsubstituted, saturated cyclic amino group, R^6 represents a hydrogen atom, a halogen atom, a nitro group or a protected

or unprotected amino group, X, Y and Z may be the same or different and each independently represents a nitrogen atom, -CH= or $-CR^7=$ in which R^7 represents a lower alkyl group, a halogen atom or a cyano group with a proviso that at least one of X, Y and Z represents a nitrogen atom, and W represents a nitrogen atom or $-CR^8=$ in which R^8 represents a hydrogen atom, a halogen atom or a lower alkyl group - and salts thereof have excellent antimicrobial potency and are useful as synthetic antimicrobial agents, and a PCT international application was filed on them (WO 97/11068 A).

The present inventors have proceeded with further research. As a result, it has been found that among the above-described pyridonecarboxylic acid derivatives (I), 1-(6-amino-3,5-difluoropyridin-2-yl)-8-bromo-7-(3-ethylamino-azetidin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid - which has a 6-amino-3,5-difluoropyridinyl group at the 1-position, an ethylaminoazetidinyl group at the 7-position, and a bromine atom at the 8-position, and represented by the following formula:



- and its salts have excellent properties that they have extremely good antimicrobial potency and broad antimicrobial spectrum covering resistant bacteria, do not show phototoxicity which is toxicity specific to quinolone and are lower in antihypertensive effect and side effects to skin, such as eruption, than known compounds of similar structures, and moreover, are long in blood half-life, extremely high in bioavailability, and extremely useful as preventives and therapeutics for various infectious diseases, leading to the completion of the present invention.

Described specifically, the present invention provides 1-(6-amino-3,5-difluoropyridin-2-yl)-8-bromo-7-(3-ethylamin oazetidin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carbo xylic acid (hereinafter called "Compound 1") or a salt thereof.

The present invention also provides a medicine comprising as an active ingredient Compound 1 or a salt thereof.

The present invention also provides a medicinal composition comprising Compound 1 or a salt thereof and a pharmaceutically acceptable carrier.

The present invention further provides use of Compound 1 or a salt thereof as a medicine.

The present invention still further provides a method for the treatment of an infectious disease, which comprises administering Compound 1 or a salt thereof.

Best Modes for Carrying Out the Invention

Compound 1 of the present invention can be formed into both acid addition salts and base addition salts. It is to be noted that those forming chelates with boron compounds are also included in such salts.

Examples of the acid addition salts can include (a) salts with mineral acids such as hydrochloric acid, sulfuric acid and phosphoric acid, (b) salts with organic carboxylic acids such as formic acid, acetic acid, citric acid, trichloroacetic acid, trifluoroacetic acid, fumaric acid and maleic acid, and (c) salts with sulfonic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, mesitylene-sulfonic acid and naphthalenesulfonic acid, while examples of the base addition salts can include (a') salts with alkali metals such as sodium and potassium, (b') salts with alkaline earth metals such as calcium and magnesium, (c') the ammonium salt, (d') salts with nitrogen-containing organic bases such as trimethylamine, triethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, diethylamine, cyclohexylamine, procaine, dibenzylamine, N-benzyl-β-phenethylamine, 1-ephenamine and N,N'-dibenzyl-ethylenediamine. Illustrative of the boron compounds are boron halides such as boron fluoride, and lower acyloxyborons such as acetoxyboron. Of these, acid addition salts are preferred, with the maleate, the methanesulfonate,

the p-toluenesulfonate and the hydrochloride being particularly preferred.

Compound 1 or the salt thereof according to the present invention can exists not only in the non-solvated form but also in the form of the hydrate or a solvate. Accordingly, the compounds according to the present invention each embrace its all crystalline forms, its hydrate, and its solvates.

Compound 1 or the salt according to the present invention can each be produced by a desired process. An exemplary process can be illustrated as follows:



wherein R^1 and R^2 represent lower alkyl groups, and R^3 represents a hydrogen atom or an amino-protecting group (for example, t-butyl, benzyl, p-methoxybenzyl, or 1,1,3,3-tetramethyl-butyl).

Compound 1 of the present invention can be obtained by reacting an orthoformate ester such as ethyl orthoformate or methyl orthoformate with the compound (A) to form an acrylate ester derivative (B), reacting the acrylate ester derivative with an amino compound (C) to yield a compound (D), subjecting the compound (D) to a cyclizing reaction to obtain a compound (E), hydrolyzing the compound (E) into a compound (F), and then reacting the compound (F) with 3-ethylaminoazetidine.

The reaction between the compound (A) and the orthoformate ester can be conducted generally at 0 to 160°C preferably at 50 to 150°C, and the reaction time may be generally 10 minutes to 48 hours, preferably 1 to 10 hours. The orthoformate ester can be used preferably in an equimolar amount or greater relative to the compound (A), notably in a molar amount about 1 to 10 times as much as the compound (A). It is preferred to add, as a reaction promoter, a carboxylic acid anhydride such as acetic anhydride. This carboxylic acid anhydride can be used preferably in an equimolar amount or greater relative to the compound (A), notably in a molar amount about 1 to 10 times as much as the compound (A).

The reaction with the compound (C) is conducted in a solventless manner or in an appropriate solvent. Any solvent can be used in this reaction insofar as it does not affect the reaction. Illustrative are aromatic hydrocarbons such as benzene, toluene and xylene; ethers such as diethyl ether,

tetrahydrofuran, dioxane, monoglyme and diglyme; aliphatic hydrocarbons such as pentane, hexane, heptane and ligroin; halogenated hydrocarbons such as methylene chloride, chloroform and carbon tetrachloride; aprotic polar solvents such as dimethylformamide and dimethylsulfoxide; and alcohols such as methanol, ethanol and propanol. This reaction can be conducted generally at 0 to 150°C preferably at 0 to 100°C, and the reaction time is 10 minutes to 48 hours in general. The compound (C) can be used in an equimolar amount or greater relative to the compound (A), notably in a molar amount 1 to 2 times as much as the compound (A).

As an alternative process, an acetal such as N,N-dimethylformamide dimethylacetal or N,N-dimethylformamide diethylacetal is reacted to the compound (A), followed by a further reaction with the compound (C) to yield the compound (D). Any solvent can be used in the reaction with the acetal insofar as it does not affect the reaction. Illustrative are those exemplified above. This reaction can be conducted generally at 0 to 150°C, preferably at room temperature to 100°C, and the reaction time can range from 10 minutes to 48 hours, preferably from 1 to 10 hours.

Next, the reaction in which the compound (D) is subjected to the cyclizing reaction to obtain the compound (E) is conducted in the presence or absence of a basic compound in a solvent. Any solvent can be used in this reaction insofar as it does not

affect the reaction. Illustrative are aromatic hydrocarbons such as benzene, toluene and xylene; ethers such as diethyl ether, tetrahydrofuran, dioxane, monoglyme and diglyme; halogenated hydrocarbons such as methylene chloride, chloroform and carbon tetrachloride; aprotic polar solvents such as dimethylformamide and dimethylsulfoxide; and alcohols such as methanol, ethanol and propanol. Usable as the basic compound can include, for example, alkali metals such as metallic sodium and metallic potassium; metal hydrides such as sodium hydride and calcium hydride; inorganic salts such as sodium hydroxide, potassium hydroxide, sodium carbonate and potassium carbonate; alkoxides such as sodium methoxide, sodium ethoxide and potassium t-butoxide; metal fluorides such as sodium fluoride and potassium fluoride; and organic bases such as triethylamine and 1,8-diazabicyclo[5.4.0]undecene (DBU). The temperature of the reaction ranges generally from 0 to 200°C, preferably from room temperature to 180°C, and the reaction can be completed in 5 minutes to 24 hours in general. The basic compound can be used in an equimolar amount or greater relative to the compound (D), notably in a molar amount 1 to 2 times as much as the compound (D).

Elimination of the carboxyl-protecting group as R^1 and the amino-protecting group as R^3 by hydrolysis of the compound (E) makes it possible to obtain the compound (F).

To the hydrolysis, reaction conditions employed in

ordinary hydrolyses are all applicable. The hydrolysis can be effected, for example, in the presence of a basic compound such as sodium hydroxide, potassium hydroxide, sodium carbonate or potassium carbonate, a mineral acid such as hydrochloric acid, sulfuric acid or hydrobromic acid, or an organic acid such as p-tolunenesulfonic acid in a solvent, for example, water, an alcohol such as methanol, ethanol or propanol, an ether such as tetrahydrofuran or dioxane, a ketone such as acetone or methyl ethyl ketone, or acetic acid, or a mixed solvent thereof. The reaction can be conducted generally at room temperature to 180°C, preferably at room temperature to 140°C, and the reaction time can generally range from 1 to 24 hours.

Further, the compound (F) is reacted to 3-ethylamino-azetidine to obtain Compound 1 of the present invention.

This reaction can be conducted in a solvent which does not affect the reaction, for example, an aromatic hydrocarbon such as benzene, toluene or xylene, an alcohol such as methanol or ethanol, an ether such as tetrahydrofuran, dioxane or monoglyme, a halogenated hydrocarbon such as methylene chloride, chloroform or carbon tetrachloride, an aprotic polar solvent such as dimethylformamide, diemthylsulfoxide or N-methylpyrrolidone, acetonitrile, or pyridine, in the presence of an acid-neutralizing agent as needed, for example sodium carbonate, calcium carbonate, triethylamine or

1,8-diazabicyclo[5.4.0]undecene (DBU), at room temperature to 160°C. The reaction time can range from several minutes to 48 hours, with a range of from 10 minutes to 24 hours being preferred. 3-Ethylaminoazetine can be used in an equimolar amount or greater relative to the compound (F), preferably in a molar amount 1 to 5 times as much as the compound (F).

Compound 1 can be converted into an acid addition salt or a base addition salt by a method known *per se* in the art.

This reaction can be conducted in a polar solvent, for example, an alcohol such as methanol or ethanol, or water, in the presence of a mineral acid such as hydrochloric acid, sulfuric acid or phosphoric acid, an organic carboxylic acid such as formic acid, acetic acid, citric acid, trichloroacetic acid, trifluoroacetic acid, fumaric acid or maleic acid, an organic sulfonic acid such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, mesitylene-sulfonic acid or naphthalenesulfonic acid, a basic compound such as sodium hydroxide, potassium hydroxide, calcium hydroxide or magnesium hydroxide, or a nitrogen-containing organic base such as ammonia, trimethylamine, triethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methyl-piperidine, N-methylmorpholine, diethylamine, cyclohexyl-amine, procaine, dibenzylamine, N-benzyl-β-phenethylamine, 1-efenamine or N,N'-dibenzylethylenediamine, at room temperature or with heating as needed.

Incidentally, the starting compound (A) can be produced, for example, by the process disclosed in any one of the following publications or by a similar process.

(1) J. Heterocyclic Chem., **22**, 1033 (1985)

(2) Liebigs Ann. Chem., 29 (1987)

(3) J. Med. Chem., **31**, 991 (1988)

(4) J. Org. Chem., **35**, 930 (1970)

(5) JP 62-246541 A

(6) JP 63-26272 A

(7) JP 63-145268 A

(8) J. Med. Chem., **29**, 2363 (1986)

(9) J. Fluorin. Chem. **28**, 361 (1985)

(10) JP 63-198664 A

(11) JP 63-264461 A

(12) JP 63-104974 A

On the other hand, the reactant compound (C) can be produced by a desired process. For example, it can be produced by substituting an amine derivative for a halogen atom bonded to a carbon atom, which is a constituent of a 6-membered ring, in accordance with a known halogen-amine substitution reaction such as that disclosed in WO 97/11068 A or WO 97/38971 A.

The compound of the present invention obtained as described above can be isolated and purified in a manner known *per se* in the art. Depending on the conditions for isolation and purification, it is obtained in the form of a salt or in the

form of a free carboxylic acid or a free amine. These two forms can be converted from one to the other as desired, and the compound of the present invention can be produced in an intended form.

Compound 1, which has a 6-amino-3,5-difluoropyridinyl group at the 1-position, an ethylaminoazetidinyl group at the 7-position and a bromine atom at the 8-position, and its salts obtained as described above, as will be demonstrated in Tests 1-4, have effects unpredictable from the structure-activity correlations accepted to date in connection with the pyridonecarboxylic acid derivatives represented by the formula (I), that is, have a long blood half-life when administered orally, and show an extremely high value of 78% in terms of bioavailability as calculated from an AUC up to 24th hour after administration while retaining excellent properties such as extremely good antimicrobial potency and non-exhibition of phototoxicity which is toxicity specific to quinolone. Further, Compound 1 an its salts also have excellent properties that they are lower in antihypertensive effect and side effects to skin, such as eruption, than known compounds of similar structures.

Compound 1 and its salts according to the present invention can each be formulated as an antimicrobial agent together with pharmaceutically acceptable carriers into compositions for parenteral administration such as injection, rectal administration or installation or oral administration in solid or liquid forms.

Exemplary preparations for injection can include pharmaceutically acceptable, sterile, aqueous or non-aqueous solutions, suspensions and emulsions. Illustrative or non-aqueous carriers, diluents, solvents and vehicles are propylene glycol, polyethylene glycol, vegetable oils, for example, olive oil, and injectable organic esters, for example, ethyl oleate. Such solutions can also contain additives such as preservatives, moistening agents, emulsifiers and dispersants as needed. These injections can be sterilized, for example, by filtration them through bacterial filters or by adding, immediately before use, sterilizing agents as are or in the form of sterile solid compositions soluble in some other sterile media for injection.

To preparations for instillatory administration, solubilizers, preservatives, isotonicities, thickeners and the like can be added as needed in addition to the compounds according to the present invention.

Exemplary solid preparations for oral administration can include capsules, tablets, pills, powders and granules. Upon formulation of such solid preparations, the compounds according to the present invention are generally mixed with at least one inert extender, for example, sucrose, lactose or starch. In the formulation of ordinary preparations, materials other than inert extenders, such as lubricants (for example, magnesium stearate), may also be used. In capsules, tablets and pills,

buffers may be used. To tablets and pills, enteric coatings may be applied.

Exemplary liquid preparations for oral administration can include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs, contain commonly-employed inert diluents, for example, water. In addition to such inert diluents, additives such as wetting agents, emulsifying or suspending agents, sweeteners, seasonings and flavors may also be added.

Preparations for rectal administration can contain, in addition to the compounds according to the present invention, excipients such as cacao butter and suppository wax.

The dosage of each compound of the present invention varies depending upon the properties of the compound, the administration route, the desired treatment period and other factors. In general, however, its daily dosage may preferably range from about 0.1 to 1,000 mg/kg, with a range of from about 0.5 to 100 mg/kg being particularly preferred. Further, this daily dosage can be administered in 2 to 4 portions as desired.

Examples

The present invention will hereinafter be described in further detail by Examples and Referential Examples.

Referential Example 1

Synthesis of ethyl

8-bromo-1-[6-(t-butylamino)-3,5-difluoropyridin-2-yl]-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate

To a chloroform solution (5 mL) in which ethyl 3-ethoxy-2-(3-bromo-2,4,5-trifluorobenzoyl)acrylate prepared from ethyl 3-bromo-2,4,5-trifluorobenzoylacetate (1.32 g) in a manner known *per se* in the art was dissolved, 2-amino-6-(t-butylamino)-3,5-difluoropyridine was added under TLC monitoring of the reaction until conversion into an amino acrylate derivative was completed. The reaction mixture was concentrated under reduced pressure to obtain a yellow solid residue. To the residue, anhydrous potassium carbonate (1.2 g) and N,N-dimethylformamide (2 mL) were added, and the mixture was stirred at 90℃ for 15 minutes. The mixture was allowed to cool down. Chloroform (30 mL) and distilled water (300 mL) were added, and the mixture was allowed to separate into layers. The chloroform layer was washed twice with distilled water (300 mL), dried over anhydrous magnesium sulfate, concentrated under reduced pressure, and then left over. The precipitate was collected by filtration, and washed successively with ethanol and diisopropyl ether in this order to obtain the title compound (1.41 g) as a colorless powder.

Melting point: 198-203°C

^{1}H-NMR($CDCl_3$) δ:

1.38(s,9H), 1.40(t,J=7Hz,3H), 4.04(q,J=7Hz,2H),

4.71(brs,1H), 7.20(dd,J=8Hz,10Hz,1H),

8.36(dd,J=9Hz,10Hz,1H), 8.54(s,1H).

Referential Example 2

Synthesis of

1-(6-amino-3,5-difluoropyridin-2-yl)-8-bromo-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

Ethyl 8-bromo-1-[6-(t-butylamino)-3,5-difluoro-pyridin-2-yl]-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (1.38 g) was added to a liquid mixture of 12% hydrochloric acid (3.5 mL) and acetic acid (3.5 mL), and the mixture was heated for 5 hours under stirring and reflux. Subsequent to addition of distilled water (5 mL), the mixture was allowed to cool down. The precipitate was collected by filtration, and washed successively with ethanol and diisopropyl ether in this order to obtain the title compound (1.10 g) as a colorless powder.

Melting point: 272-278°C

^{1}H-NMR(D_6-DMSO)δ:

6.80(s,2H), 7.99(t,J=9Hz,1H), 8.38(t,J=9Hz,1H),

8.93(s,1H).

Example 1

Synthesis of

1-(6-amino-3,5-difluoropyridin-2-yl)-8-bromo-7-(3-ethylaminoazetidin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (Compound 1)

3-Ethylaminoazetidine (700 mg), 1-(6-amino-3,5-difluoropyridin-2-yl)-8-bromo-6,7-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (1.5 g), N-methyl-pyrrolidine (2.0 g) and dimethylsulfoxide (4.5 g) were combined, and the mixture was heated under stirring at 40°C for 24 hours. After the mixture was allowed to cool down, isopropyl ether (10 mL) was added, the mixture was stirred, and a clear layer at the top of the mixture was removed. The same procedure was repeated once more, and the residue was concentrated under reduced pressure. Ethanol (5 mL) was added, and the mixture was heated under stirring at 70°C for 30 minutes. The precipitated solid was collected by filtration. The title compound (1.38 g) was obtained.

Appearance: Colorless powder

Melting point: 195-196°C

^{1}H-NMR (D_6-DMSO) δ:

0.99(t,J=7Hz,3H), 2.48(q,J=7Hz,2H), 4.05-4.15(m,2H), 4.35-4.42(m,1H), 4.60-4.69(m,2H), 6.74(brs,2H), 7.88(d,J=14Hz,1H), 7.93(t,J=9Hz,1H), 8.69(s,1H).

Example 2

Synthesis of 1-(6-amino-3,5-difluoropyridin-2-yl)-8-bromo-7-(3-ethylaminoazetidin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid maleate (Compound 2)

1-(6-Amino-3,5-difluoropyridin-1-yl)-6-fluoro-4-oxo-1

,4-dihydroquinoline-3-carboxylic acid (1.38 g) was added to ethanol (13 mL), and to the mixture, maleic acid (400 mg) was added gradually. The mixture was heated under stirring at 70°C for 5 hours. After the mixture was allowed to cool down, a solid was collected by filtration. The solid was washed with ethanol. The title compound (1.33 g) was obtained.

Appearance: Colorless powder

Melting point: 196-199°C

^{1}H-NMR(D_6-DMSO) δ:

1.16(t,J=7Hz,3H), 2.93(q,J=7Hz,2H), 3.99-4.06(m,1H), 4.41-4.48(m,1H), 4.50-4.56(m,1H), 4.67-4.74(m,1H), 4.74-4.82(m,1H), 6.02(s,2H), 6.76(brs,2H), 7.95(t,J=9Hz,1H), 7.97(d,J=14Hz,1H), 8.75(s,1H).

Tests

The results of tests on the compound of the present invention for antimicrobial effects, phototoxicity and *in vivo* distribution will be described in Tests 1-4. As comparative compounds, the following compounds disclosed in WO 97/11068 A and commercially-available ciprofloxacin (CPFX) and levofloxacin (LVFX) were used.

Comparative Compound 1:

1-(6-amino-3,5-difluoropyridin-2-yl)-8-bromo-7-(3-methylaminoazetidin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid.

Comparative Compound 2:

1-(6-amino-3,5-difluoro-pyridin-2-yl)-8-chloro-7-(3-ethylam
inoazetidin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-car
boxylic acid.

CPFX:

1-cyclopropyl-6-fluoro-7-(1-piperadinyl)-1,4-dihydro-4-oxoq
uinoline-3-carboxylic acid.

LVFX:

S(-)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazin
yl)-7-oxo-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic
acid.

(1) Antimicrobial effects

Their minimum growth inhibitory concentrations (MICs: μg/mL) were determined in accordance with the standard method of the Japan Society of Chemotherapy [Chemotherapy, **29**(1), 76 (1981)]. The results are presented in Table 1.

Table 1

	Comp'd 1	Comp. Comp'd 1	Comp. Comp'd 2	CPFX	LVFX
S. aureus 209P	0.013	0.013	0.013	0.2	0.2
MRSA W200	0.013	0.025	0.025	0.78	0.39
S.epidermidis IFO12293	0.025	0.05	0.05	1.56	0.78
E. faecalis IFO12580	0.39	0.39	0.78	1.56	1.56
M. luteus IFO12708	0.39	0.39	0.78	3.13	0.78
B. subtilis ATCC6633	0.025	0.05	0.025	0.05	0.1
E. coli NIHJ-JC2	0.025	0.013	0.025	0.025	0.05
K. pneumoniae KC-1	0.05	0.025	0.05	0.05	0.1
P vulgaris IFO3167	0.1	0.1	0.2	0.05	0.05
S. marcescens IFO3736	1.56	1.56	1.56	0.2	0.78
P. aeruginosa IFO3445	0.78	0.39	0.39	0.39	0.78
P. aeruginosa E-2	1.56	0.78	1.56	0.78	1.56

(2) Phototoxicity test

A phototoxicity test was performed by the following procedure.

Female ICR mice (5 to 6 weeks old) were intravenously administered with the test compounds (40 mg/kg/10 mL), respectively, and were exposed for 4 hours to ultraviolet rays (320 to 400 nm, 1.8 $mW/cm^2/sec$). Their ears were observed for abnormality at 0 hour (immediately after the exposure) and after 24 and 48 hours.

Ear abnormality was ranked by the following standards:

no abnormality (0 point), mild erythema (1 point), medium erythema (2 points), and severe erythema or edema (3 points). The results are presented in Table 2.

Table 2

	0 hour (point, frequency)	24 hours	48 hours
Compound 1	0, 0/3	0, 0/3	0, 0/3
Comp. Comp'd 1	0, 0/3	0, 0/3	0, 0/3
Comp. Comp'd 2	0.7, 2/3	0, 0/3	0, 0/3

(3) Antibacterial effects on clinically-isolated quinolone resistant pneumococci

Using agar plates added with 5% defibrinated sheep blood, minimum growth inhibition concentrations (MICs; μg/mL) against certain pneumococci were determined in accordance with the standard method of the Japan Society of Chemotherapy [Chemotherapy, **29**(1), 76 (1981)]. The results are presented in Table 3.

Table 3

	Compound 1	Comp.Comp'd 1	CPFX	LVFX
Isolated coccus 1	0.03	0.06	8	2
Isolated coccus 5	0.12	0.5	64	32

From the results of Table 1 to Table 3, the compound according to the present invention exhibited antimicrobial activities comparable with or better than the comparative compounds, and was also negative in phototoxicity.

(4) *In vivo* pharmacokinetic study

An investigation was made on the absorption and excretion of the compounds of the present invention in and from dogs.

A 0.5% suspension of one of the test compounds in methyl cellulose (10 mg/mL/kg) was forcedly administered *per os* to 2-4 years old, male beagles fasted for 16 to 17 hours. After the administration, blood samples were collected on the 0.25^{th}, 0.5^{th}, 1^{st}, 2^{nd}, 4^{th}, 6^{th}, 8^{th} and 24^{th} hours, and serum samples were obtained. To determine urinary excretion rates, urine samples were also collected up to 24^{th} hour after the administration. The concentrations of the test compound in the serum samples and urine samples were measured by the paper disk method making use of *Bacillus subtilis* ATCC6633 as a test bacterium, and the absorption and excretion were ranked. The results so obtained are presented in Table 4.

Table 4

	N	C_{max} (μg/mL)	T_{max} (hr)	$T_{1/2}$ (hr)	AUC 0-8 hr (μg·hr/mL)	Urinary excretion rate (%)
Compound 1	3	4.82	1	3.8	22.8	19.8
Compound 2	3	3.73	1	4.8	17.6	17.4
Comparative Compound 1	2	2.35	0.5	2.0	8.54	14.8
The maleate salt of Comparative Compound 1	3	1.49	1	3.8	7.66	16.7

It has been confirmed from Table 4 that the compounds of the present invention have *in vivo* pharmacokinetic study significantly improved over the comparative compounds.

Industrial Applicability

Compound 1 and its salts according to the present invention have characteristic properties that, when administered orally, they exhibit long blood half-time and extremely high bioavailability while retaining the properties that they are extremely high in antimicrobial effects and low in toxicity. Compound 1 and its salts also have excellent properties that they are lower in antihypertensive effect and side effects to skin, such as eruption, than known compounds of similar structures. Compound 1 and its salts, therefore, can be used widely as preventives and therapeutics for various infectious diseases of human and animals and also as fish drugs, agrichemicals, food preservatives and the like. Further, Compound 1 of the present invention is expected to have antiviral effects, especially anti-HIV (human immunodeficiency virus) effects, and is considered to be effective for the prevention or treatment of AIDS.

CLAIMS

1. 1-(6-Amino-3,5-difluoropyridin-2-yl)-8-bromo-7-(3-ethylaminoazetidin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a salt thereof.

2. A medicine comprising as an active ingredient 1-(6-amino-3,5-difluoropyridin-2-yl)-8-bromo-7-(3-ethylaminoazetidin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a salt thereof.

3. A medicine according to claim 2, which is an antimicrobial medicine.

4. A medicinal composition comprising 1-(6-amino-3,5-difluoropyridin-2-yl)-8-bromo-7-(3-ethylaminoazetidin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a salt thereof and a pharmaceutically acceptable carrier.

5. A medicinal composition according to claim 4, which is an antimicrobial medicinal composition.

6. Use of 1-(6-amino-3,5-difluoropyridin-2-yl)-8-bromo-7-(3-ethylaminoazetidin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a salt thereof as a medicine.

7. A method for the treatment of an infectious disease, which comprises administering 1-(6-amino-3,5-difluoropyridin-2-yl)-8-bromo-7-(3-

ethylaminoazetidin-1-yl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a salt thereof.

Declaration and Power of Attorney For Patent Application

WP0026 US1

特許出願宣言書及び委任状

Japanese Language Declaration

日本語宣言書

下記の氏名の発明者として、私は以下の通り宣言します。

As a below named inventor, I hereby declare that:

私の住所、私書箱、国籍は下記の私の氏名の後に記載された通りです。

My residence, post office address and citizenship are as stated next to my name.

下記の名称の発明に関して請求範囲に記載され、特許出願している発明内容について、私が最初かつ唯一の発明者（下記の氏名が一つの場合）もしくは最初かつ共同発明者（下記の名称が複数の場合）であると信じています。

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled.

QUINOLINECARBOXYLIC ACID DERIVATIVE OR SALTS THEREOF

キノリンカルボン酸誘導体又はその塩

上記発明の明細書は、

the specification of which

☐ 本書に添付されています。

☐ is attached hereto.

☒ 2000年 6月 22日に提出され、米国出願番号または特許協定条約国際出願番号を PCT/JP00/04096 とし、

☒ was filed on June 22, 2000 as ~~United States Application Number or~~ PCT International Application Number PCT/JP00/04096 and was amended on _____ (if applicable).

（該当する場合）_____に訂正されました。

私は、特許請求範囲を含む上記訂正後の明細書を検討し、内容を理解していることをここに表明します。

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

私は、連邦規則法典第37編第1条56項に定義されるとおり、特許資格の有無について重要な情報を開示する義務があることを認めます。

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

Japanese Language Declaration
(日本語宣言書)

私は、米国法典第35編119条（a）-（d）項又は365条（b）項に基づき下記の、米国以外の国の少なくとも一ヵ国を指定している特許協力条約365（a）項に基づく国際出願、又は外国での特許出願もしくは発明者証の出願についての外国優先権をここに主張するとともに、優先権を主張している、本出願の前に出願された特許または発明者証の外国出願を以下に、枠内をマークすることで、示しています。

I hereby claim foreign priority under Title 35, United States Code, Section 119 (a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)
外国での先行出願

(Number) (番号)	(Country) (国名)	(Day/Month/Year Filed) (出願年月日)	Priority Claimed 優先権主張 Yes はい	No いいえ
11-187492	Japan	01/07/1999	☒	☐
			☐	☐

私は、第35編米国法典119条（e）項に基づいて下記の米国特許出願規定に記載された権利をここに主張いたします。

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

(Application No.) (出願番号)	(Filing Date) (出願日)

私は、下記の米国法典第35編120条に基づいて下記の米国特許出願に記載された権利、又は米国を指定している特許協力条約365条（c）に基づく権利をここに主張します。また、本出願の各請求範囲の内容が米国法典第35編112条第1項又は特許協力条約で規定された方法で先行する米国特許出願に開示されていない限り、その先行米国出願書提出日以降で本出願書の日本国内または特許協力条約国際提出日までの期間中に入手された、連邦規則法典第37編1条56項で定義された特許資格の有無に関する重要な情報について開示義務があることを認識しています。

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of application.

(Application No.) (出願番号)	(Filing Date) (出願日)	(Status: Patented, Pending, Abandoned) (現況：特許許可済、係属中、放棄済)

私は、私自信の知識に基づいて本宣言書中で私が行なう表明が真実であり、かつ私の入手した情報と私の信じるところに基づく表明が全て真実であると信じていること、さらに故意になされた虚偽の表明及びそれと同等の行為は米国法典第18編第1001条に基づき、罰金または拘禁、もしくはその両方により処罰されること、そしてそのような故意による虚偽の声明を行なえば、出願した、又は既に許可された特許の有効性が失われることを認識し、よってここに上記のごとく宣誓を致します。

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Japanese Language Declaration
(日本語宣言書)

委任状：私は下記の発明者として、本出願に関する一切の手続きを米特許商標局に対して遂行する弁理士または代理人として、下記の者を指名いたします。
(弁護士、または代理人の指名及び登録番号を明記のこと)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: *(list name and registration number)*

022850

書類送付先

Send Correspondence to:

022850

直接電話連絡先：（名前及び電話番号）

Direct Telephone Calls to: (name and telephone number)

(703) 413-3000

単独発明者または第一の共同発明者の氏名 矢崎　明	Full name of sole or first joint inventor 1-00 Akira YAZAKI
発明者の署名 Akira Yazaki 日付 Nov. 26, 2001	Inventor's signature Date
住所 739-1195 日本国広島県高田郡甲田町下甲立１６２４ 湧永製薬株式会社内	Residence C/O WAKUNAGA PHARMACEUTICAL CO., LTD. 1624, Shimokotachi, Koda-cho, Takata-gun, 739-1195 Japan
国籍 日本国	Citizenship JAPANESE JPX
郵便の宛先 住所に同じ	Post Office Address SAME AS ABOVE
第二の共同発明者の氏名 新野　良子	Full name of second joint inventor, if any 2-00 Yoshiko NIINO
第二の共同発明者の署名 Yoshiko Niino 日付 Nov. 26, 2001	Second joint Inventor's signature Date
住所 739-1195 日本国広島県高田郡甲田町下甲立１６２４ 湧永製薬株式会社内	Residence C/O WAKUNAGA PHARMACEUTICAL CO., LTD. 1624, Shimokotachi, Koda-cho, Takata-gun, 739-1195 Japan
国籍 日本国	Citizenship JAPANESE JPX
郵便の宛先 住所に同じ	Post Office Address SAME AS ABOVE

(第三以降の共同発明者についても同様に記載し、署名すること)

(Supply similar information and signature for third and subsequent joint inventors.)

Japanese Language Declaration
(日本語宣言書)

第三の共同発明者の氏名 倉本 康弘	Full name of third joint inventor, if any 3rd Yasuhiro KURAMOTO
第三の共同発明者の署名 Yasuhiro Kuramoto 日付 Nov. 26, 2001	Third joint inventor's signature Date
住所 739-1195 日本国広島県高田郡甲田町下甲立１６２４ 湧永製薬株式会社内	Residence C/O WAKUNAGA PHARMACEUTICAL CO., LTD. 1624, Shimokotachi, Koda-cho, Takata-gun, 739-1195 Japan
国籍 日本国	Citizenship JPX JAPANESE
郵便の宛先 住所に同じ	Post Office Address SAME AS ABOVE

第四の共同発明者の氏名 平尾 勇造	Full name of fourth joint inventor, if any 4th Yuzo HIRAO
第四の共同発明者の署名 Yuzo Hirao 日付 Nov. 26, 2001	Fourth joint Inventor's signature Date
住所 739-1195 日本国広島県高田郡甲田町下甲立１６２４ 湧永製薬株式会社内	Residence C/O WAKUNAGA PHARMACEUTICAL CO., LTD. 1624, Shimokotachi, Koda-cho, Takata-gun, 739-1195 Japan
国籍 日本国	Citizenship JPX JAPANESE
郵便の宛先 住所に同じ	Post Office Address SAME AS ABOVE

第五の共同発明者の氏名 大下 嘉弘	Full name of fifth joint inventor, if any 5th Yoshihiro OHSHITA
第五の共同発明者の署名 Yoshihiro Ohshita 日付 Nov. 26, 2001	Fifth joint Inventor's signature Date
住所 739-1195 日本国広島県高田郡甲田町下甲立１６２４ 湧永製薬株式会社内	Residence C/O WAKUNAGA PHARMACEUTICAL CO., LTD. 1624, Shimokotachi, Koda-cho, Takata-gun, 739-1195 Japan
国籍 日本国	Citizenship ~~JAPANESE~~ JPX
郵便の宛先 住所に同じ	Post Office Address SAME AS ABOVE

第六の共同発明者の氏名 林 則博	Full name of sixth joint inventor, if any 6th Norihiro HAYASHI
第六の共同発明者の署名 Norihiro Hayashi 日付 Nov. 26, 2001	Sixth joint Inventor's signature Date
住所 739-1195 日本国広島県高田郡甲田町下甲立１６２４ 湧永製薬株式会社内	Residence C/O WAKUNAGA PHARMACEUTICAL CO., LTD. 1624, Shimokotachi, Koda-cho, Takata-gun, 739-1195 Japan
国籍 日本国	Citizenship ~~JAPANESE~~ JPX
郵便の宛先 住所に同じ	Post Office Address SAME AS ABOVE

(第六またはそれ以降の共同発明者に対しても同様な情報および署名を提供すること。)

(Supply similar information and signature for third and subsequent joint inventors.)

Japanese Language Declaration
(日本語宣言書)

第七の共同発明者の氏名　天野　浩貴	Full name of seventh joint inventor, if any 710 Hirotaka AMANO
第七の共同発明者の署名　Hirotaka Amano　日付 Nov. 26, 2001	Seventh joint inventor's signature Date
住所　739-1195 日本国広島県高田郡甲田町下甲立１６２４ 湧永製薬株式会社内	Residence C/O WAKUNAGA PHARMACEUTICAL CO., LTD. 1624, Shimokotachi, Koda-cho, Takata-gun, 739-1195 Japan
国籍　日本国	Citizenship JAPANESE JPX
郵便の宛先　住所に同じ	Post Office Address SAME AS ABOVE

第八の共同発明者の氏名	Full name of eighth joint inventor, if any
第八の共同発明者の署名　日付	Eighth joint inventor's signature Date
住所	Residence
国籍	Citizenship
郵便の宛先	Post Office Address

第九の共同発明者の氏名	Full name of ninth joint inventor, if any
第九の共同発明者の署名　日付	Ninth joint inventor's signature Date
住所	Residence
国籍	Citizenship
郵便の宛先	Post Office Address

第十の共同発明者の氏名	Full name of tenth joint inventor, if any
第十の共同発明者の署名　日付	Tenth joint inventor's signature Date
住所	Residence
国籍	Citizenship
郵便の宛先	Post Office Address